Is Cramer-Krasselt/Chicago about to lose one of its big pharmaceutical accounts? A source familiar with the situation said the Rozerem account may be about to exit the agency. Rozerem is a drug similar to Ambien that is used to treat insomnia.
A C-K spokeswoman said she had no indication the Rozerem business was about to leave the shop, but she did indicate the account has been dormant at the agency for the past two years -- meaning no new advertising for the brand has been done during that time.
Cramer-Krasselt has had the Rozerem business since 2005. The C-K spokeswoman said no creative teams are currently assigned exclusively to the Rozerem business. But a source said that if Rozerem were to depart the agency, there might be layoffs. A Rozerem spokeswoman said she knew of no immediate plans to move the account. But she acknowledged that the C-K account is dormant and that there are no plans at present to do any consumer-focused advertising.
Lewis Lazare has written the Media Mix column for the Chicago Sun-Times for the past seven and a half years.

Leave a comment